



## **InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market**

**NEW YORK, TORONTO, and HERZLIYA, Israel – October 12, 2021** – [InterCure Ltd.](http://www.intercure.co) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company's common stock.

Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD\$7.03 per share (CAD \$8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD\$2,975,730 (CAD \$3,790,238 per share or NIS 9,608,631).

### **About InterCure (dba Canndoc)**

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: <http://www.intercure.co>.

To be added to InterCure's email distribution list, please email [InterCure@kcsa.com](mailto:InterCure@kcsa.com) with "InterCure" in the subject.

### **Contact:**

#### **InterCure Ltd.**

Amos Cohen, Chief Financial Officer  
[amos@canndoc-pharma.com](mailto:amos@canndoc-pharma.com)

#### **KCSA Strategic Communications**

Investor and Media Relations  
[InterCure@kcsa.com](mailto:InterCure@kcsa.com)



## **InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market**

**NEW YORK, TORONTO, and HERZLIYA, Israel – October 12, 2021** – [InterCure Ltd.](http://www.intercure.co) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company's common stock.

Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD\$7.03 per share (CAD \$8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD\$2,975,730 (CAD \$3,790,238 per share or NIS 9,608,631).

### **About InterCure (dba Canndoc)**

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: <http://www.intercure.co>.

To be added to InterCure's email distribution list, please email [InterCure@kcsa.com](mailto:InterCure@kcsa.com) with "InterCure" in the subject.

### **Contact:**

#### **InterCure Ltd.**

Amos Cohen, Chief Financial Officer  
[amos@canndoc-pharma.com](mailto:amos@canndoc-pharma.com)

#### **KCSA Strategic Communications**

Investor and Media Relations  
[InterCure@kcsa.com](mailto:InterCure@kcsa.com)